https://www.selleckchem.com/pr....oducts/fingolimod.ht
Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for non-small cell lung cancer (NSCLC). We assessed the efficacy and toxicity of afatinib + cetuximab versus afatinib alone in the first-line treatment of advanced -mutant NSCLC. In this phase II, randomized, open-label study, patients with stage III/IV -positive NSCLC were randomly assigned (11) to receive afatinib (group A) or afatinib + cetuximab (group A + C). Oral afatinib 40
Curtir
Comentario
Compartilhar
